MDX-1342, a fully human monoclonal antibody (HuMAb), targets the CD19 membrane receptor with high specificity and affinity. It exhibits antibody-dependent cellular cytotoxicity (ADCC) and is utilized in researching B-lymphocyte malignancies and autoimmune diseases [1].

MDX-1342 (0-100 μg/mL; 30 min) binds to Ramos, Raji, and ARH-77 cells, demonstrating EC50 values of 0.

MDX-1342 administered intravenously at doses of 0.03, 0.3, 3, and 30 mg/kg in a 200 μL volume enhances survival in a dose-dependent manner in a mouse B-cell lymphoma model [1]. At single doses of 0.1 or 1 mg/kg, MDX-1342 exhibits low nanomolar affinity for CD19 in cynomolgus monkeys, increased binding to cynomolgus monkey FcγRIIIa, and demonstrates effective B-cell depletion in vivo [1].

Human

Monoclonal

Unconjugated